OpGen (OPGN) Stock Rating Lowered by Zacks Investment Research

Share on StockTwits

Zacks Investment Research lowered shares of OpGen (NASDAQ:OPGN) from a buy rating to a hold rating in a research report report published on Thursday, Zacks.com reports.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

Separately, Alliance Global Partners began coverage on OpGen in a research report on Friday, March 1st. They set a buy rating and a $2.30 target price on the stock.

OPGN stock opened at $0.53 on Thursday. OpGen has a twelve month low of $0.52 and a twelve month high of $2.90. The stock has a market cap of $4.60 million, a P/E ratio of -0.24 and a beta of 1.04. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.20 and a current ratio of 1.32.

OpGen (NASDAQ:OPGN) last released its earnings results on Tuesday, February 26th. The medical research company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.09). OpGen had a negative return on equity of 232.38% and a negative net margin of 453.73%. On average, sell-side analysts predict that OpGen will post -0.87 earnings per share for the current fiscal year.

In related news, CEO Evan/ Fa Jones acquired 417,000 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were bought at an average cost of $0.60 per share, with a total value of $250,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 7.10% of the stock is currently owned by insiders.

An institutional investor recently bought a new position in OpGen stock. Virtu Financial LLC acquired a new stake in shares of OpGen Inc (NASDAQ:OPGN) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 115,918 shares of the medical research company’s stock, valued at approximately $70,000. Virtu Financial LLC owned approximately 1.34% of OpGen at the end of the most recent quarter. 6.81% of the stock is owned by institutional investors and hedge funds.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Recommended Story: When is a capital gain realized?

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Royal Bank of Canada Trims Russel Metals  Target Price to C$25.00
Royal Bank of Canada Trims Russel Metals Target Price to C$25.00
Turquoise Hill Resources  Cut to “Speculative Buy” at TD Securities
Turquoise Hill Resources Cut to “Speculative Buy” at TD Securities
Western Forest Products  Stock Rating Lowered by Raymond James
Western Forest Products Stock Rating Lowered by Raymond James
Cedar Fair, L.P.  Expected to Earn Q2 2019 Earnings of $0.65 Per Share
Cedar Fair, L.P. Expected to Earn Q2 2019 Earnings of $0.65 Per Share
HELLA GMBH & CO KGAA  PT Set at €43.00 by Goldman Sachs Group
HELLA GMBH & CO KGAA PT Set at €43.00 by Goldman Sachs Group
Duerr  Given a €35.00 Price Target by Deutsche Bank Analysts
Duerr Given a €35.00 Price Target by Deutsche Bank Analysts


 
© 2006-2019 Zolmax.